ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer

You, Shuhui; Gong, Chengcheng; Li, Yi; Xie, Yizhao; Li, Yumeng; Zhao, Yannan*; Wang, Biyun*复旦大学; 1
Frontiers in Endocrinology2023-10-10DOI: 10.3389/fendo.2023.1270453
5阅读
引用收藏
分享

摘要

ObjectiveDespite the promising efficacy of the novel antibody-drug conjugate trastuzumab deruxtecan in treating Hormone Receptor (HoR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-low metastatic breast cancer (MBC), its categorization as a distinct entity remains disputed, as does the divergence in its endocrine and chemotherapy outcomes. This study aimed to elucidate the clinical characteristics, primary/metastatic lesion HER2 expression, and treatment outcomes of HoR-positive/HER2-low patients.MethodsWe included HoR-positive/HER2-negative MBC patients who underwent 1st and 2nd line endocrine treatment from July 2010 to October 2022 at the Fudan University Shanghai Cancer Center, comparing the clinical pathological characteristics, HER2 expression in primary/metastatic lesions, treatment, and therapeutic effects of the HER2-low and HER2-zero groups.ResultsAmong the 458 HoR-positive/HER2-negative MBC patients, 54.37% (249/458) were HER2-low. The HER2-low group and the HER2-zero group had similar clinical pathological characteristics and similar progression-free survival (PFS) of 1st and 2nd line endocrine treatment (median PFS: 8.05 months vs 10.12 months, p=0.114, HR 1.257, 95% CI 0.771 to 1.028). The PFS of the HER2-low and HER2-zero groups was also similar, treated with different endocrine drugs (including aromatase inhibitors, tamoxifen/toremifene, fulvestrant, palbociclib, and everolimus). However, the HER2-low group had significantly shorter PFS during 1st and 2nd line chemotherapy compared to the HER2-zero group (median PFS: 8.64 vs 9.03 months, p=0.027, HR 0.841, 95% CI 0.721-0.980). Additionally, 41.18% (63/153) of patients exhibited a change in HER2 expression between primary and metastatic lesions. Notably, patients whose HER2 status changed from zero to low expression had significantly prolonged PFS during chemotherapy compared to those who maintained low HER2 expression (median PFS: 14.29 vs 11.27 months, p=0.048, HR 0.597, 95% CI 0.358-0.996).ConclusionIn HoR-positive MBC, patients with low and zero HER2 expression have similar clinical characteristics and respond similarly to endocrine treatment, but the chemotherapy effect is worse in the HER2-low patients. Moreover, the transformation of HER2 status from primary to metastatic lesions may have potential influence on chemotherapy outcomes. Therefore, the expression and heterogeneity of HER2 should be considered in clinical decisions.

学科与关键词

关键词
hormone receptor-positiveHER2-lowmetastatic breast cancerendocrine therapychemotherapyevolutionprognosis
相关
加载中…
  • Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
    Yang, Man; Sun, Jiale; Liu, Liqiong; Kong, Xiangyi; Lin, Dongcai; Zhou, Hong; Gao, Jidong*Scientific Reports, 2023, 13(1): 12382.被引 3
  • Survival differences between HER2-0 and HER2-low-expressing breast cancer- A meta-analysis of early breast cancer patients
    Yang, Ciqiu; Zhang, Xiaoqi; Chen, Yitian; Li, Peiyong; Zhang, Junsheng; Xu, Aiqi; Huang, Na; Liang, Minting; Chen, Yilin; Wang, Kun*Critical Reviews in Oncology/Hematology, 2023, 185: 103962.被引 4
  • Clinicopathological characteristics of breast cancer patients with HER-2 low expression received neoadjuvant therapy
    Zhang, Shiyuan; Yu, Xiao; Xiu, Yuting; Qiao, Kun; Jiang, Cong*; Huang, Yuanxi*Oncology, 2024, 102(2): 122-130.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2023-10-10
卷期
第 14 卷
页码
1270453
DOI
10.3389/fendo.2023.1270453
成果收录
SCIE
资助标注
The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from National Natural Science Foundation of China (82373340), "Soaring" Program of the Shanghai Anti-Canc [82373340]; National Natural Science Foundation of China [SACA-AX202209]; Soaring" Program of the Shanghai Anti-Cancer Association [KC2022-ZZ-0091-4]; Beijing Science and Technology Innovation Medical Development Foundation [Y-pierrefabre202102-0002]; CSCO-Pierre Fabre Oncology Research Foundation [82102722]; National Youth Science Fund Project of National Natural Science Foundation of China [2021-2023, ZDXK202103]; Guangzhou Key Discipline of Medicine

作者

  • Y

    You, Shuhui (第一作者)

    fudan univ

  • G

    Gong, Chengcheng

    fudan univ

查看全部 7 位作者收起作者
  • L

    Li, Yi

  • X

    Xie, Yizhao

    fudan univ

  • L

    Li, Yumeng

  • Z

    Zhao, Yannan (通讯)

    fudan univ

  • W

    Wang, Biyun (通讯)

    fudan univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417